doxorubicin

Doxorubicin (Adriamycin) 是一种有细胞毒性的蒽环类抗生素，具有肿瘤化疗作用。它抑制DNA 拓扑异构酶 I 和拓扑异构酶 II，IC50分别为0.8 μM 和2.67 μM，从而抑制 DNA 复制。它下调AMPK 的基础磷酸化以及下游 acetyl-CoA 羧化酶。它诱导凋亡和自噬 。

Doxorubicin hydrochloride (Adriamycin) 属于蒽环类抗生素，是人类 DNA 拓扑异构酶 I II 抑制剂 (IC50=0.8 2.67 μM)。Doxorubicin hydrochloride 具有细胞毒性和抗肿瘤活性。Doxorubicin hydrochloride 可降低 AMPK 及其下游靶蛋白乙酰辅酶 A 羧化酶的磷酸化，还可诱导凋亡和自噬。

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) 是一种具有口服活性的质子泵抑制剂。它是取代的苯并咪唑，是H+ K+-ATPase 抑制剂。它可改善 pH 值稳定性，具有抗分泌和抗溃疡的作用。它联合阿霉素可显著增加肿瘤生长延迟。

Pantoprazole (BY1023) 是一种质子泵抑制剂，用于短期治疗由胃食管反流病引起的食管糜烂和溃疡。它联合阿霉素可显著增加肿瘤生长延迟。它是一种取代的苯并咪唑，是H+ K+-ATPase 抑制剂，可改善 pH 值稳定性，具有抗分泌和抗溃疡的作用。

Pantoprazole sodium (Pantecta) 是一种具有口服活性的质子泵抑制剂，是一种取代的苯并咪唑，是H+ K+-ATPase 抑制剂，IC50为 6.8 μM。它可以改善 pH 值稳定性，具有抗分泌和抗溃疡的作用。它联合阿霉素可显著增加肿瘤生长延迟。

Doxorubicin-SMCC is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Doxorubicin-SMCC (GMP)是 Doxorubicin-SMCC 的 GMP 级别试剂。Doxorubicin-SMCC 是一种不可断裂的抗体-药物偶联物（ADC）合成用的衔接剂。

N-(Iodoacetamido)-Doxorubicin is an ADC linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

MA-PEG4-VC-PAB-DMEA-Doxorubicin 是一种硫醇反应型 Drug-linker,Doxorubicin 是一种有细胞毒性的蒽环类广谱抗生素，常用作肿瘤化疗剂，MA-PEG4-VC-PAB-DMEA-Doxorubicin 可用于抗体-药物偶联物（ADC）的合成。

Zoptarelin doxorubicin, also known as AEZS-108, is an LHRH agonist. Zoptarelin doxorubicin is a peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation

Azide-PEG4-VC-PAB-Doxorubicin 为链接剂 Azide-PEG4-VC-PAB 与毒性分子 Doxorubicin 结合形成，适用于抗体药物偶联物（ADCs）的制备。

Cholesterol-doxorubicin 是一种胆固醇耦联物，具备优良的储存稳定性、较低的血液毒性和可控的药物输送特性，适用于药物递送研究。

NSC348884 是一种核磷蛋白抑制剂，可破坏寡聚体形成并诱导细胞凋亡，在不同的癌细胞系中以 IC50 为 1.7-4.0 μM 抑制细胞增殖。

Adriamycin Aglycone, also known as Doxorubicinone, is an oncolytic agent. It is a metabolite of Doxorubicin which binds to the DNA minor-groove.

Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker.

Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.

DOX−NOP1 is a molecular hybrid covalently joining doxorubicin (DOX) and NOP1. DOX−NOP1 showed similar increased toxicity toward resistant cancer cells and, in addition, lower cardiotoxicity than DOX.

Nemorubicin (PNU 152243) 是一种 Doxorubicin 衍生物，具有抗肿瘤活性。它需要完整的核苷酸切除修复系统才能发挥活性。它对多药耐药表型的多种肿瘤细胞系具有细胞毒性。

MC-DOXHZN hydrochloride is an albumin-binding prodrug of Doxorubicin. Doxorubicin is a DNA topoisomerase II inhibitor.

Aldoxorubicin hydrochloride 是 Doxorubicin (DNA 拓扑异构酶 II 抑制剂) 的白蛋白结合前药。Aldoxorubicin hydrochloride 在酸性条件下从白蛋白中释放出来。 Aldoxorubicin hydrochloride 显示出有效的抗肿瘤活性。

Aldoxorubicin has effective antitumor activities in various cancer cell lines and in murine tumor models. Aldoxorubicin is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitors).

Doxorubicinol is the major circulating metabolite of doxorubicin with antineoplastic acitivity.

Doxorubicinol hydrochloride, also known as 13-Dihydroadriamycin hydrochloride, is a secondary alcohol metabolite derived from Doxorubicin.

N,N-Dimethyldoxorubicin为一Doxorubicin类似物，表现出对多种肿瘤细胞系的显著细胞毒性，其半数抑制浓度(IC50s)均小于0.3 μM。